Australian Institute of Health and Welfare (2020) Impacts of COVID-19 on Medicare Benefits Scheme and Pharmaceutical Benefits Scheme service use, AIHW, Australian Government, accessed 18 August 2022.
Australian Institute of Health and Welfare. (2020). Impacts of COVID-19 on Medicare Benefits Scheme and Pharmaceutical Benefits Scheme service use. Retrieved from https://pp.aihw.gov.au/reports/health-care-quality-performance/covid-impacts-on-mbs-and-pbs
Impacts of COVID-19 on Medicare Benefits Scheme and Pharmaceutical Benefits Scheme service use. Australian Institute of Health and Welfare, 17 December 2020, https://pp.aihw.gov.au/reports/health-care-quality-performance/covid-impacts-on-mbs-and-pbs
Australian Institute of Health and Welfare. Impacts of COVID-19 on Medicare Benefits Scheme and Pharmaceutical Benefits Scheme service use [Internet]. Canberra: Australian Institute of Health and Welfare, 2020 [cited 2022 Aug. 18]. Available from: https://pp.aihw.gov.au/reports/health-care-quality-performance/covid-impacts-on-mbs-and-pbs
Australian Institute of Health and Welfare (AIHW) 2020, Impacts of COVID-19 on Medicare Benefits Scheme and Pharmaceutical Benefits Scheme service use, viewed 18 August 2022, https://pp.aihw.gov.au/reports/health-care-quality-performance/covid-impacts-on-mbs-and-pbs
Get citations as an Endnote file:
The Australian Government subsidises the cost of a wide range of prescription medicines through two separate schemes, the Pharmaceutical Benefits Scheme (PBS) and the Repatriation Pharmaceutical Benefits Scheme (RPBS). Claims for reimbursement for the supply of PBS- or RPBS-subsidised medicines are submitted by pharmacies through Services Australia for processing, and are provided to the Australian Government Department of Health. Subsidies for prescription medicines are available to all Australian residents who hold a current Medicare card, and overseas visitors from countries with which Australia has a Reciprocal Health Care Agreement. Patients pay a contribution to the cost of the medicine (co-payment), and the Australian Government covers the remaining cost. This remaining cost is referred to as the benefit paid.
PBS data in this report are from records of prescriptions dispensed under the two schemes, where either:
PBS data cover all prescriptions dispensed by approved suppliers, including community pharmacies, public and private hospital pharmacies, and dispensing doctors.
PBS does not cover:
Medicines dispensed through alternative arrangements where the patient cannot be identified, such as direct supply to Aboriginal health services, are excluded.
Provision of some medicines may be under-represented in those remote areas, particularly for the Northern Territory with a high proportion of Aboriginal and Torres Strait Islander people who can access medicines through Aboriginal health services.
The number of prescriptions represents the total number of times that a prescribed medicine is supplied to a patient. For individual prescriptions where the quantity dispensed varied from the listed maximum quantity, no adjustment was made for increased or reduced quantity supplied. The supply was counted as one prescription.
Prescriptions dispensed and government benefits paid in this report are presented by month which is based on the date the medicine was supplied to the patient.
The Schedule of Pharmaceutical Benefits (the Schedule) is released monthly and provides information on the arrangements for the prescribing and supply of pharmaceutical benefits under the PBS. The Schedule lists all of the ready-prepared items subsidised under the PBS.
PBS listed medicines are organised into Anatomical Therapeutic Chemical (ATC) classification groups according to the body system or organ on which they act. See the World Health Organization Collaborating Centre for Drug Statistics Methodology (WHOCC) for further information on the ATC classification system.
The ATC Classification used in this report is from the Australian Government Department of Health’s version of the WHOCC ATC Classification, which has some minor differences from the WHOCC version, based upon a particular medicine’s usage in Australia. The Schedule of Pharmaceutical Benefits according to ATC groups can be viewed via browsing by body system.
This web report has categorised PBS listed medicines into “program types” which reflect the groupings in the Schedule and are described below.
Most PBS medicines are dispensed by community pharmacies and used by patients at home. These are known as ‘General Schedule’ medicines.
Section 100 of the National Health Act 1953 provides for an alternative method of medicines supply to patients when normal PBS arrangements are not appropriate.
Section 100 programs include:
Separate sub-schedules exist for specific prescribers or for a specific cohort of the population. These include:
Items annotated with an asterisk (*) were excluded from visualisation titled “Number of scripts dispensed by PBS program”.
Greater Capital City Statistical Areas (GCCSAs) are geographical areas that represent the functional extent of each of Australia’s capital cities. This geographical area has been developed by the Australian Bureau of Statistics and includes people who regularly socialise, shop or work within the city, but live in the small towns and rural areas surrounding the city. GCCSAs are not bound by a minimum population size criterion.
Medicare enrolment postcode is used as a proxy for the patient residence as it corresponds to most people’s usual residence. If the patient postcode was unknown or invalid, the postcode of the dispensing pharmacy is used instead.
PHNs are organisations that connect health services across a specific geographic area (PHN areas). There are 31 PHN areas that cover the whole of Australia with the boundaries defined by the Australian Government Department of Health.
Statistical Areas Level 3 (SA3s) is a type of geographical classification defined by the Australian Bureau of Statistics (ABS) to provide a regional breakdown of Australia. There are 336 geographical areas covering Australia, with boundaries defined by the ABS. Each SA3 generally has a population of between 30,000 and 130,000 people. Allocation to an SA3 for PBS data is based on the patient’s usual place of residence, rather than where they received treatment.
We'd love to know any feedback that you have about the AIHW website, its contents or reports.
The browser you are using to browse this website is outdated and some features may not display properly or be accessible to you. Please use a more recent browser for the best user experience.